We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+34.92%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$237M
Cap. Flow
+$422M
Cap. Flow %
39.55%
Top 10 Hldgs %
35.09%
Holding
191
New
51
Increased
37
Reduced
12
Closed
55

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.6M
2
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$16.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.7M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$6.77M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$10.1M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.16M
3
SLRN
ACELYRIN
SLRN
+$7.92M
4
PCVX icon
Vaxcyte
PCVX
+$7.26M
5
GPCR icon
Structure Therapeutics
GPCR
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
101
Tectonic Therapeutic
TECX
$529M
$977K 0.09%
59,855
– –
PRQR icon
102
ProQR Therapeutics
PRQR
$243M
$936K 0.09%
472,625
– –
LNTH icon
103
Lantheus
LNTH
$6.49B
$930K 0.09%
+15,000
New +$1.02M
SLNO
104
CALL
DELISTED
Soleno Therapeutics
SLNO
$853K 0.08%
+21,200
New +$603K
KZR
105
DELISTED
Kezar Life Sciences
KZR
$809K 0.08%
85,339
– –
MIST icon
106
Milestone Pharmaceuticals
MIST
$138M
$773K 0.07%
462,828
– –
OKUR
107
PUT
OnKure Therapeutics
OKUR
$154M
$692K 0.06%
+43,260
New +$2.7M
IMUX icon
108
CALL
Immunic
IMUX
$190M
$675K 0.06%
+45,000
New +$551K
OKUR
109
OnKure Therapeutics
OKUR
$154M
$674K 0.06%
+42,130
New +$2.63M
TYRA icon
110
Tyra Biosciences
TYRA
$1.9B
$667K 0.06%
48,170
– –
ALLK
111
DELISTED
Allakos
ALLK
$647K 0.06%
237,056
-550,000
-70% -$1.24M
ELEV
112
DELISTED
Elevation Oncology
ELEV
$629K 0.06%
1,171,939
– –
GPCR icon
113
Structure Therapeutics
GPCR
$3.41B
$592K 0.06%
14,524
-123,300
-89% -$7.07M
VERV
114
PUT
DELISTED
Verve Therapeutics
VERV
$576K 0.05%
41,300
+38,887
+1,612% +$482K
IMTX icon
115
Immatics
IMTX
$1.18B
$516K 0.05%
49,031
– –
TCON
116
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$484K 0.05%
138,277
– –
TPST icon
117
Tempest Therapeutics
TPST
$13.7M
$465K 0.04%
+8,123
New +$385K
HOOK
118
DELISTED
HOOKIPA Pharma
HOOK
$430K 0.04%
53,078
– –
ANEB
119
DELISTED
Anebulo Pharmaceuticals
ANEB
$382K 0.04%
157,862
– –
TARA icon
120
Protara Therapeutics
TARA
$220M
$353K 0.03%
188,664
– –
KPTI icon
121
Karyopharm Therapeutics
KPTI
$43.5M
$346K 0.03%
26,667
– –
CYTK icon
122
PUT
Cytokinetics
CYTK
$10.5B
$292K 0.03%
3,500
+1,465
+72% +$53K
VRNA
123
DELISTED
Verona Pharma
VRNA
$257K 0.02%
367,468
+48,877
+15% +$722K
CRSP icon
124
CALL
CRISPR Therapeutics
CRSP
$4.73B
$244K 0.02%
3,900
+3,861
+9,900% +$213K
RLMD icon
125
Relmada Therapeutics
RLMD
$557M
$167K 0.02%
40,369
– –
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Ikarian Capital held 191 positions worth $1.07B, up 28% from $831M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ikarian Capital deployed $422M of net new capital in Q4 2023, opening 51 new positions and adding to 37 existing holdings. Its largest new stake was argenx: 70,000 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 32% a quarter earlier.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $9.16M trimmed.

  • Ikarian Capital's largest Q4 2023 buy was argenx: 70,000 shares worth $26.5M.
  • Ikarian Capital added most to Disc Medicine in Q4 2023, an estimated $2.67M increase.
  • Ikarian Capital's biggest Q4 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $9.16M.
  • Ikarian Capital fully exited Akero Therapeutics in Q4 2023, selling an estimated $10.1M.
  • Ikarian Capital's ten largest holdings make up 35% of its $1.07B portfolio in Q4 2023.
  • Ikarian Capital opened 51 new positions and closed 55 in Q4 2023.
  • Ikarian Capital's portfolio value rose 28% quarter-over-quarter to $1.07B.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.